ALGLUCOSIDASE ALFA — A NEW STAGE IN THE THERAPY OF INFANTILE POMPE DISEASE
https://doi.org/10.15690/pf.v11i5.1171
Abstract
Pompe disease is a rare severe hereditary disease caused by excessive glycogen storage in organs and target tissues due to the acid α-glucosidase gene mutation. Infantile and adult Pompe disease is characterized by involvement of cardiovascular, respiratory and muscular systems in the pathological process. The only specific method of treating Pompe disease is enzyme replacement therapy (intravenous administration of recombinant human acid glucosidase), the effectiveness whereof depends on the time the therapy started. Since such a therapy was introduced into practice, Pompe disease mortality decreased by 79%. 6 children with infantile Pompe disease were observed and treated at the cardiovascular care unit of the Scientific Center of Children’s Health in 2011‑2014. The article presents a clinical case demonstrating capabilities of diagnosing infantile Pompe disease in Russia and effective application of alglucosidase alfa in 4-month-old child.
About the Authors
E. N. Basargina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. N. Arkhipova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
V. S. Ermolenko
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Hirshhorn R., Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (eds). The metabolic and molecular bases of inherited disease. New York: McGraw Hill. 2001. Р. 3389–3420.
2. Nicolino M., Byrne B., Wraith J.E. et al. Clinical outcomes after long-term treatment with alglucosidasealfa in infants and children with advanced Pompe disease. Genet Med. 2009; 11 (3): 210–209.
3. Kishnani P.S., Hwu W.L., Mander H. et al. A retrospective, multinational, multicenter study on the natural history of infantile onset Pompe disease. J Pediatrics. 2006; 148: 671–676.
4. Umapathysivam К., Hopwood J.J., Meikle P.J. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. 2001; 47: 1378−1383.
5. Amalfitano A., Bengur A.R., Morse R.P. et al. Recombinant human acid ― glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001; 3: 132–138.
6. Myozyme [Summary of Product Characteristics]. Genzyme Europe BV. 2006.
7. Angelini C., Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep. 2012; 12: 70–75.
8. Kishnani P.S. et al. Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology. 2007 January 9; 68: 99−109.
9. Chien Y.H., Chiang S.C., Zhang X.K. et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008; 122 (1): 39–45.
Review
For citations:
Basargina E.N., Arkhipova E.N., Ermolenko V.S. ALGLUCOSIDASE ALFA — A NEW STAGE IN THE THERAPY OF INFANTILE POMPE DISEASE. Pediatric pharmacology. 2014;11(5):93-97. https://doi.org/10.15690/pf.v11i5.1171
Views:
1223
Email this article 